| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476010 | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Dec, 2024
(7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5714520 | FRESENIUS KABI USA | Propofol compostion containing edetate |
Mar, 2015
(9 years ago) | |
| US5731355 | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Mar, 2015
(9 years ago) | |
| US5731356 | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Mar, 2015
(9 years ago) | |
| US5908869 | FRESENIUS KABI USA | Propofol compositions containing edetate |
Mar, 2015
(9 years ago) | |
|
US5714520 (Pediatric) | FRESENIUS KABI USA | Propofol compostion containing edetate |
Sep, 2015
(8 years ago) | |
|
US5731355 (Pediatric) | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Sep, 2015
(8 years ago) | |
|
US5731356 (Pediatric) | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Sep, 2015
(8 years ago) | |
|
US5908869 (Pediatric) | FRESENIUS KABI USA | Propofol compositions containing edetate |
Sep, 2015
(8 years ago) | |
|
US8476010 (Pediatric) | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Jun, 2025
(1 year, 1 month from now) | |
Diprivan is owned by Fresenius Kabi Usa.
Diprivan contains Propofol.
Diprivan has a total of 10 drug patents out of which 8 drug patents have expired.
Expired drug patents of Diprivan are:
- US5714520
- US5731355
- US5731356
- US5908869
- US5714520*PED
- US5731355*PED
- US5731356*PED
- US5908869*PED
Diprivan was authorised for market use on 02 October, 1989.
Diprivan is available in injectable;injection dosage forms.
Diprivan can be used as method for limiting the potential for microbial growth in the drug product, method of improving the time for administration or the time between changes of giving sets for the drug product, method of producing anesthesia.
The generics of Diprivan are possible to be released after 01 June, 2025.
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: Method of producing anesthesia; Method for limiting the potential for microbial growth in the drug product; Method of improving the time for administration or the time between changes of giving sets f...
Dosage: INJECTABLE;INJECTION
DIPRIVAN family patents
